Italy Insulin Drugs And Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 531.86 Million |
| Market Size (2029) | USD 572.96 Million |
| CAGR (2024 - 2029) | 1.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Italy Insulin Drugs And Delivery Devices Market Analysis
The Italy Insulin Drugs and Delivery Devices Market size is estimated at USD 531.86 million in 2024, and is expected to reach USD 572.96 million by 2029, growing at a CAGR of 1.5% during the forecast period (2024-2029).
Between February and March 2021, the Italian Association of Diabetes Doctors (AMD) conducted a survey among its members to assess the impact of the SARS-CoV-2 pandemic on the volume of care provided by diabetes services in Italy, as well as to analyse the measures implemented during the national lockdown. Through planning, urban health initiatives promote healthy lifestyles. Health literacy refers to an individual's ability to comprehend, access, and apply information in ways that promote and maintain good health. Italy has joined the Action Network on Measuring Population and Organizational Health Literacy (M-POHL), which conducted a survey between 2019 and 2021 to establish a baseline level of health literacy that can be used to plan health policy measures to improve health literacy and track the health outcomes of such measures over time.
The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS offers to citizens, with or without partial contributions based on a patient's income. The Insulin pens are free of cost for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.
Technological development is gaining momentum in the insulin devices market. Over the years, in fact, several technological innovations have been developed that have led to the creation of new types of devices that are more comfortable for patients compared to the traditional ones. Such advantages have helped the rise in the adoption of these products in the Italian market.
Italy Insulin Drugs And Delivery Devices Market Trends
Growing Diabetes and Obesity Population in Italy
According to the International Diabetes Federation (IDF), diabetes will affect nearly 10% of the global adult population (536.6 million people) by 2021, with 1.2 million children and adolescents (aged 19) who have type 1 diabetes. In Italy, the percentages are lower: 5.6%, according to the National Institute of Statistics (ISTAT), and 4.7%, according to PASSI surveillance data collected among adults aged 18-69. ISTAT and PASSI discovered that prevalence was higher in the south than in the center and north.
The Italian National Healthcare Service (NHS) ensures universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need. Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery. The Italian health system is highly decentralized, with most administrative and organizational powers held by the Regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus.
The Insulin Pumps Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.
Insulin Pump held a major market share in the insulin delivery devices market in 2021 and is expected to grow with a CAGR of more than 4.3% during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM) people. Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
Italy Insulin Drugs And Delivery Devices Industry Overview
Italy Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.
Italy Insulin Drugs And Delivery Devices Market Leaders
-
Roche
-
Medtronics
-
Novo Nordisk
-
Sanofi
-
Eli Lilly
*Disclaimer: Major Players sorted in no particular order
Italy Insulin Drugs And Delivery Devices Market News
- April 2022: CamDiab and Ypsomed announced the partnership to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of diabetes management for people with diabetes. The new integrated AID system is designed to connect Abbott's FreeStyle Libre 3 sensor, the world's smallest and most accurate continuous glucose monitoring sensor, to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump creating a smart, automated process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person's glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.
- January 2022: A clinical research study started to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetes.
Italy Insulin Drugs And Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Basal or Long-acting Insulins
- 5.1.1.1 Lantus (Insulin Glargine)
- 5.1.1.2 Levemir (Insulin Detemir)
- 5.1.1.3 Toujeo (Insulin Glargine)
- 5.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.5 Basaglar (Insulin Glargine)
- 5.1.2 Bolus or Fast-acting Insulins
- 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
- 5.1.2.2 Humalog (Insulin lispro)
- 5.1.2.3 Apidra (Insulin glulisine)
- 5.1.2.4 FIASP (Insulin aspart)
- 5.1.2.5 Admelog (Insulin lispro Sanofi)
- 5.1.3 Traditional Human Insulins
- 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
- 5.1.3.2 Humulin
- 5.1.3.3 Insuman
- 5.1.4 Combination Insulins
- 5.1.4.1 NovoMix (Biphasic Insulin aspart)
- 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
- 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
- 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
- 5.1.5 Biosimilar Insulins
- 5.1.5.1 Insulin Glargine Biosimilars
- 5.1.5.2 Human Insulin Biosimilars
-
5.2 Device
- 5.2.1 Insulin Pumps
- 5.2.1.1 Insulin Pump Devices
- 5.2.1.2 Insulin Pump Reservoirs
- 5.2.1.3 Insulin Infusion sets
- 5.2.2 Insulin Pens
- 5.2.2.1 Cartridges in reusable pens
- 5.2.2.2 Disposable insulin pens
- 5.2.3 Insulin Syringes
- 5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Novo Nordisk
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly
- 7.1.4 Biocon
- 7.1.5 Julphar
- 7.1.6 Medtronic
- 7.1.7 Ypsomed
- 7.1.8 Becton Dickinson
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityItaly Insulin Drugs And Delivery Devices Industry Segmentation
Italy's Insulin Drugs and Delivery Devices Market witnessed USD 0.4 billion in the current year. Italy's Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Drug | Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) |
| Humalog (Insulin lispro) | ||
| Apidra (Insulin glulisine) | ||
| FIASP (Insulin aspart) | ||
| Admelog (Insulin lispro Sanofi) | ||
| Drug | Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Drug | Combination Insulins | NovoMix (Biphasic Insulin aspart) |
| Ryzodeg (Insulin degludec and Insulin aspart) | ||
| Xultophy (Insulin degludec and Liraglutide) | ||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | ||
| Drug | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Device | Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | ||
| Insulin Infusion sets | ||
| Device | Insulin Pens | Cartridges in reusable pens |
| Disposable insulin pens | ||
| Device | Insulin Syringes | |
| Insulin Jet Injectors |
Italy Insulin Drugs And Delivery Devices Market Research FAQs
How big is the Italy Insulin Drugs and Delivery Devices Market?
The Italy Insulin Drugs and Delivery Devices Market size is expected to reach USD 531.86 million in 2024 and grow at a CAGR of 1.5% to reach USD 572.96 million by 2029.
What is the current Italy Insulin Drugs and Delivery Devices Market size?
In 2024, the Italy Insulin Drugs and Delivery Devices Market size is expected to reach USD 531.86 million.
Who are the key players in Italy Insulin Drugs and Delivery Devices Market?
Roche, Medtronics, Novo Nordisk, Sanofi and Eli Lilly are the major companies operating in the Italy Insulin Drugs and Delivery Devices Market.
What years does this Italy Insulin Drugs and Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the Italy Insulin Drugs and Delivery Devices Market size was estimated at USD 524 million. The report covers the Italy Insulin Drugs and Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Italy Insulin Drugs and Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Italy Insulin Drugs And Delivery Devices Industry Report
Statistics for the 2024 Italy Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Insulin Drugs And Delivery Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
